In an international study,

OGIVRI was proven to be as safe and effective

as HERCEPTIN for the treatment of HER2+ metastatic breast cancer.8

  • Baseline

  • Monitor every 3 months in case of significant cardiac dysfunction withhold treatment and monitor every 4 weeks

  • Monitor every 6 months
    (at least for 2 years)

  • Immediately prior
    to starting Ogivri

  • While receiving
    Ogivri treatments

  • After completing
    Ogivri treatments

*Normal cells also have HER2, so HER2 targeted therapies like OGIVRI may also affect healthy cells which may cause serious side effects.